Yazar "Reck, M." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ?50%: KEYNOTE-598 3-year follow-up(Elsevier, 2022) Abreu, D. Rodriguez; Reck, M.; Sendur, N.; Park, K.; Lee, D. H.; Cicin, I.; Yumuk, P. F.[Abstract Not Available]Öğe Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3(Elsevier Science Inc, 2020) Selvaggi, G.; Wakelee, H. A.; Mok, T.; Wu, Y. -L.; Reck, M.; Chiappori, A.; Cicin, I.[Abstract Not Available]Öğe Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.(Elsevier Science Inc, 2021) Selvaggi, G.; Wu, Y.; Wang, Z.; Wu, G.; Poddubskaya, E.; Reck, M.; Mok, T.[Abstract Not Available]
